These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2045842)

  • 1. Drug promotion and labeling in developing countries: an update.
    Lee PR; Lurie P; Silverman MM; Lydecker M
    J Clin Epidemiol; 1991; 44 Suppl 2():49S-55S. PubMed ID: 2045842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The drugging of the Third World.
    Silverman M; Lee PR; Lydecker M
    Int J Health Serv; 1982; 12(4):585-96. PubMed ID: 7141775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The drug swindlers.
    Silverman M; Lydecker M; Lee PR
    Int J Health Serv; 1990; 20(4):561-72. PubMed ID: 2265874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug promotion: the Third World revisited.
    Silverman M; Lee PR; Lydecker M
    Int J Health Serv; 1986; 16(4):659-67. PubMed ID: 2430907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When medicine becomes a disease.
    Arabia; 1986 Mar; 5(55):32-6. PubMed ID: 12340711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug companies' evidence to justify advertising.
    Wade VA; Mansfield PR; McDonald PJ
    Lancet; 1989 Nov; 2(8674):1261-3. PubMed ID: 2573769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
    Vilhelmsson A; Davis C; Mulinari S
    PLoS Med; 2016 Jan; 13(1):e1001945. PubMed ID: 26812151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global marketing of cholesterol-lowering drugs as therapy.
    Elimimian JU; Gilmore JM; Singletary TJ
    J Hosp Mark Public Relations; 2006; 16(1-2):15-28. PubMed ID: 17194684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overpromotion of drugs in international product package inserts.
    Osifo NG
    Trop Doct; 1983 Jan; 13(1):5-8. PubMed ID: 6836735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The epidemiology of drug promotion.
    Silverman M
    Int J Health Serv; 1977; 7(2):157-66. PubMed ID: 856741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substandard medicines in resource-poor settings: a problem that can no longer be ignored.
    Caudron JM; Ford N; Henkens M; Macé C; Kiddle-Monroe R; Pinel J
    Trop Med Int Health; 2008 Aug; 13(8):1062-72. PubMed ID: 18631318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical companies and their drugs on social media: a content analysis of drug information on popular social media sites.
    Tyrawski J; DeAndrea DC
    J Med Internet Res; 2015 Jun; 17(6):e130. PubMed ID: 26032738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical malpractice in drug promotion: a case-study from Brazil.
    Victora CG
    Soc Sci Med; 1982; 16(6):707-9. PubMed ID: 7089605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence of Drug Promotional Literatures Distributed by Pharmaceutical Companies to World Health Organization Ethical Criteria for Medicinal Drug Promotion.
    Prasad P; Bajracharya SR; Deo S; Lamichhane S; Pradhan PMS; Ghimire R; Pokharel A
    J Nepal Health Res Counc; 2019 Nov; 17(3):345-350. PubMed ID: 31735930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New countermeasures considered as drug counterfeiting grows.
    Schubert C
    Nat Med; 2008 Jul; 14(7):700. PubMed ID: 18607355
    [No Abstract]   [Full Text] [Related]  

  • 18. Methodology of OTA's report on drug labeling in developing countries.
    Gelband H; Corrigan J; McDonough R
    Int J Technol Assess Health Care; 1993; 9(2):238-50. PubMed ID: 8458703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs for developing countries. Uncharitable stance from Oxfam.
    Wenz C
    Nature; 1982 Dec; 300(5891):395. PubMed ID: 7144894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Early achievements of the Danish pharmaceutical industry-7].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2014; (42):31-62. PubMed ID: 25816561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.